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Abstract
Variable warfarin response during treatment initiation poses a significant challenge to providing optimal anticoagulation
therapy. We investigated the determinants of initial warfarin response in a cohort of 167 patients. During the first nine days
of treatment with pharmacogenetics-guided dosing, S-warfarin plasma levels and international normalized ratio were
obtained to serve as inputs to a pharmacokinetic-pharmacodynamic (PK-PD) model. Individual PK (S-warfarin clearance) and
PD (Imax) parameter values were estimated. Regression analysis demonstrated that CYP2C9 genotype, kidney function, and
gender were independent determinants of S-warfarin clearance. The values for Imax were dependent on VKORC1 and CYP4F2
genotypes, vitamin K status (as measured by plasma concentrations of proteins induced by vitamin K absence, PIVKA-II) and
weight. Importantly, indication for warfarin was a major independent determinant of Imax during initiation, where PD
sensitivity was greater in atrial fibrillation than venous thromboembolism. To demonstrate the utility of the global PK-PD
model, we compared the predicted initial anticoagulation responses with previously established warfarin dosing algorithms.
These insights and modeling approaches have application to personalized warfarin therapy.
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Introduction
The vitamin K antagonist, warfarin, is an oral anticoagulant
commonly prescribed to prevent and treat venous thromboembo-
lism (VTE) and decrease the risk of stroke in atrial fibrillation
(AF).[1] Warfarin therapy is complicated by the wide interindi-
vidual variation in response and dose requirements for adequate
anticoagulation. Optimal warfarin therapy is achieved by
maintaining the anticoagulation response, international normal-
ized ratio (INR), within a narrow therapeutic range of 2.0 to 3.0
for most indications. Due to the unpredictable pharmacokinetic
(PK) and pharmacodynamic (PD) responses to warfarin, initiation
of therapy is the most clinically challenging phase as the optimal
dose is often determined iteratively, guided by INR.[2]
Warfarin is administered as a racemic drug; however, the S-
warfarin enantiomer is 3–5 times more potent than R-warfarin.[3]
CYP2C9 is the primary enzyme responsible for metabolism of S-
warfarin,[4] and studies have consistently shown that CYP2C9
polymorphisms (
*2, c.430C.T, rs1799853;
*3, c.1075A.C,
rs1057910) significantly contribute to the variable warfarin
response.[5] Non-genetic factors of warfarin PK variability and
dose requirements are also important. For example, age and co-
administration with drugs that inhibit or induce CYP2C9 can alter
S-warfarin elimination.[6,7,8,9,10] Moreover, S-warfarin volume
of distribution is dependent on weight.[11,12] Taken together, it
has been estimated that PK factors determine 26-40% of warfarin
maintenance dose variability.[10,13,14]
Warfarin exerts its anticoagulation effects by inhibiting vitamin
K epoxide reductase (VKOR encoded by the VKORC1 gene), the
enzyme responsible for recycling oxidized vitamin K epoxide to its
hydroquinone form, an essential cofactor for activation of clotting
factors II, VII, IX and X.[15] It is appreciated that single
nucleotide polymorphisms (SNPs) in VKORC1 result in altered
warfarin sensitivity while rare mutations have been linked to
warfarin resistance.[8,16] Of note, the common promoter SNP
(VKORC1 -1639G.A, rs9923231) is likely the causative variation
responsible for greater warfarin sensitivity.[17,18] In addition to
CYP2C9 and VKORC1 polymorphisms, several studies have
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rs2108622), the metabolizing enzyme for vitamin K,[19] also
determines dose requirement.[20,21] Furthermore, diet has long
been considered an important environmental determinant of
warfarin response. Indeed, reduced anticoagulation response was
observed in warfarin-stabilized patients with intake of vitamin K-
rich foods,[22,23] and vitamin K status was associated with
warfarin sensitivity at the onset of treatment.[24]
With the intent of improving warfarin anticoagulation therapy,
a number of algorithms have been proposed which incorporate
genetics as well as clinical parameters to predict individualized
maintenance dose.[8,25,26] Many of the factors influencing
required maintenance dose such as age, body surface area, drug
interactions and importantly, CYP2C9 genotype relate to their
effects on S-warfarin PK parameters, such as volume of
distribution and clearance.[7,8,9,27] The influence of genetics
and clinical parameters on S-warfarin PD variability is less clear.
Although the influence of VKORC1 genetic variations and vitamin
K intake on dose and anticoagulation response is evident, the
quantitative and dynamic influence of these variables on PD
parameters, such as drug affinity and maximal inhibition, has not
been well established.[28] Moreover, there is a paucity of
information regarding the influence of other genetic and clinical
variables on S-warfarin PD variation.
In this study, we aimed to separate warfarin pharmacokinetic
factors from intrinsic pharmacodynamic factors to elucidate
crucial covariates of each, and their contribution to the overall
anticoagulation response variation. To this end, PK-PD modeling
was applied to a cohort of patients commencing warfarin therapy
using a novel initiation protocol.[29]
Materials and Methods
Study subjects and design
Patients with AF (n=61), VTE (n=98) or other conditions
(n=8) were prospectively enrolled to evaluate the safety and
efficacy of a pharmacogenetics-based warfarin initiation protocol.
Patient characteristics and clinical outcomes were described
previously in detail. [29] The inclusion criteria for study enrolment
were minimum of 18 years of age and indication for new warfarin
therapy for at least 3 months with a target INR range of 2.0 to 3.0.
Patients were excluded on the basis of diagnosis of cancer other
than non-melanoma skin cancer, alcohol or drug abuse, baseline
INR.1.4, known warfarin allergy/intolerance, terminal disease,
prior use of warfarin or vitamin K use within 2 weeks prior to
study enrolment, and pregnancy. The majority of patients were
Caucasian (95%) with mean age of 60 years (range, 19–88) and
mean weight of 84 Kg (43–155). The allelic frequencies for
VKORC1 -1639G.A and CYP4F2 c.1297G.A were 38.0% and
31.7%, respectively. The CYP2C9
*2 and
*3 allelic frequencies were
11.1% and 4.8%, respectively. There was no homozygous
CYP2C9
*3 carrier in this population. Amiodarone, statin, anti-
platelet, antibiotic, antifungal and NSAID medication use were
present in 2%, 45%, 55%, 6%, 1% and 12% of the cohort,
respectively.
The Warfarin Regimen using A Pharmacogenetics-guided
Initiation Dosing (WRAPID) protocol has been described
elsewhere.[29] Briefly, a 2-day loading dose (according to VKORC1
and CYP2C9 genotype) was administered, followed by a day 3 INR
measurement that was used in combination with the maintenance
algorithm to determine the subsequent dose. Two subsequent INR
measurements were obtained within the first 9 days of therapy
where the maintenance dose was further adjusted accordingly to
the dose adjustment nomogram. Simultaneous with INR moni-
toring, additional blood samples were collected for drug level
analysis.
This study was conducted at the London Health Sciences
Centre and The Ottawa Hospital upon approval by Research
Ethics Boards at the University of Western Ontario and Ottawa
Hospital. Patients requiring initiation of warfarin therapy were
prospectively screened for study eligibility and informed written
consent was acquired.
Genotyping
Genomic DNA was isolated with Gentra Puregene or DNA
Blood Midi extraction kit (Qiagen, Valencia, CA). At London
Health Sciences Centre, genotypes were determined by allelic
discrimination using TaqMan Drug Metabolism Genotyping
assays with the 7500 RT-PCR System (Applied Biosystems,
Carlsbad, CA). At Ottawa Health Research Institute, genotypes
were determined using the Luminex 200 system (Luminex, Austin,
TX).
Warfarin drug level analysis
Racemic warfarin and internal standard (IS) R/S-para-chloro-
warfarin were purchased from Sigma-Aldrich. Plasma was
extracted from patient blood samples within 1 hour of collection
and stored at 280uC until use. Total S-warfarin plasma
concentration was determined using liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Briefly, 300 mLo f
acetonitrile and 25 mL of IS was added to 100 mL of plasma and
centrifuged at 14,000 rpm for 20 min. The resulting supernatant
was added to 5 mM ammonium acetate pH 4 (1:3 v/v). Warfarin
and IS enantiomers were separated with the Astec CHIROBIO-
TIC
TM V Chiral Column (5 cm64.6 mm, 5 mM particle size)
using gradient elution with 5 mM ammonium acetate (pH 4) and
acetonitrile (5 to 70%) in a 10 min run time. The MS was set in
negative mode for detection of warfarin and IS with transitions
307.2 160.0 m/z and 340.8 160.0 m/z, respectively. Calibration
curves were prepared by spiking blank plasma with known
concentrations of R/S-warfarin. The lowest limit of quantification
was 1 ng/mL for both enantiomers. The interday coefficient of
variation and bias of S-warfarin quality controls was 10.5% and
9.3%.
Proteins induced by vitamin K absence factor II (PIVKA-II)
assay
PIVKA-II concentrations were analyzed with use of an enzyme-
linked immunosorbent assay kit as per manufacturer’s protocols
(Diagnostica-Stago, Parsippany, NJ).
Kidney function
We measured patient plasma creatinine concentrations by LC-
MS/MS. Briefly, creatinine and the IS, creatinine-D3, was
purchased from Sigma-Aldrich and Toronto Research Chemicals,
respectively. Creatinine and IS were separated with the reverse-
phase Hypersil Gold column (5065 mm, 5 mM particle size) using
isocratic elution with 25% 1% formic acid in water v/v and 75%
acetonitrile with 1% formic acid v/v in a 7 min run time. The MS
was set in positive mode for detection of creatinine and IS with
transitions 114.1 R 44.3 m/z and 117.1 R 47.3 m/z, respectively.
The lowest limit of quantification was 50 ng/mL. The interday
coefficient of variation and bias of creatinine quality controls was
8.7% and 6%. eGFR was estimated using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation.[30]
Renal function was categorized according the National Kidney
Foundation’s classification of chronic kidney disease.
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S-warfarin PK was described using a linear one-compartment
model with a set volume of distribution (V; 0.14 L/kg) on a per
patient basis.[12] The time-course of plasma S-warfarin concen-
tration (Cp) arose from the interplay between first-order drug
absorption (ka) and drug elimination (ke) processes. Parameter
values for ka were fixed (28.56 day
21) based on the literature.[31]
Bioavailability was assumed to be complete.[32] Individual ke
values were obtained by least squares fitting (Scientist, Micromath,
St. Louis, MO) of the concentration data during the first 9 days
with prescribed doses as input. Clearance (CL) was calculated as
the product of V and ke.
S-warfarin PD was described by an established indirect response
model which incorporates the known delay in anticoagulation
effects.[33] In this model, the rate of change in INR was modeled
using zero-order input (K) and first-order output (kout) variables.
Plasma S-warfarin levels (Cp) modulate the output response
according to classical inhibition kinetics, described by parameters
maximum inhibitory factor (Imax, i.e. inversely related to enzyme
content) and drug affinity (IC50).[34] Since VKORC1 -1639G.A
promoter SNP has been correlated with altered mRNA expression
levels, Imax values were expected to vary with VKORC1 genotype.
Rmax and kout values in the indirect response model were both
fixed at 1. The IC50 for S-warfarin was fixed at 1500 ng/mL, as
reported previously.[35] The following equation describes the PD
model.
dINR
dt
~R{INR:kout 1{
Imax:Cp
IC50zCp

The response analysis was conducted following estimation of
individual S-warfarin plasma concentrations. These estimated
drug concentrations were used in combination with measured
INRs to estimate the individual PD parameter, Imax, by least
squares fitting.
We note that clearance and Imax parameter estimates should be
considered independent of the dosing regimen and anticoagulation
responses observed in the WRAPID study because estimations of
individual warfarin clearance and individual drug concentration-
response profile are unaffected by the doses received.
Vitamin K epoxide reductase protein expression in
human liver
The collection and processing of liver samples was described
elsewhere.[36] In order to obtain a positive control for VKOR
protein analysis, the enzyme was over-expressed in cells using
previously described protocol.[37] For this purpose, human
VKORC1 cDNA was amplified from a human liver cDNA library
using primers 59-TGGAGATAATGGGCAGCACCTGGGGG-
39 (forward) and 59-GTTGAGGGCTCAGTGCCTCTTAGC-
CTTG-39 (reverse). Samples were separated by SDS-PAGE on 4–
10% gels (Invitrogen, Carlsbad, CA) and subsequently transferred
onto nitrocellulose membranes. Blots were probed with a custom
anti-VKOR antibody (kindly provided by Dr. Kathleen Berkner,
Learner Research Institute, Cleveland Clinic [38]) and subse-
quently probed with anti-rabbit horseradish peroxidise-labeled
secondary antibodies (Bio-Rad, Hercules, CA). The bands were
detected using the BM Chemiluminescence Western Blotting
Substrate (Roche, Indianapolis, IN) and KODAK ImageStation
4000 MM (Carestream, Rochester, NY). Protein expression levels
were normalized to a wild-type VKORC1 sample (HLM100),
repeated on all blots.
Determinants of warfarin kinetics and response
Regression analysis was performed to determine factors
affecting S-warfarin clearance and Imax. Since the distribution of
both of these parameters in our patient population was skewed,
square-root transformation was adopted to normalize the data.
The variables age, gender, body weight, amiodarone use, other
known interacting medications, indication for warfarin therapy,
kidney function, vitamin K status as measured by PIVKA-II,
VKORC1 genotype, CYP2C9
*2 and
*3 genotype were considered as
covariates for both S-warfarin clearance and Imax. The covariates
were added to the model according to the stepwise forward
regression. A P-value,0.05 was considered as significant and the
variable was subsequently entered into the equation; variables
included with P-values.0.1 in subsequent models were removed.
The models with significant covariates were then internally
validated through bootstrapping. Bootstrapping was achieved by
random sampling with replacements to obtain 1000 samples,
allowing estimation of the standard error and the 95% confidence
interval (CI) of parameter estimates. Potential collinearity between
variables was assessed using condition indices and variance
proportions.
The clearance and Imax regression equations were then
integrated with the PK-PD model in order to predict and
compare anticoagulation response profiles following initiation
with various nomograms for typical warfarin patients.
Statistical analysis
The Kruskal-Wallis one-way analysis of variance followed by
Tukey’s test for pairwise comparisons was employed for the
following analysis: S-warfarin concentration differences with
respect to VKORC1 genotype, influence of VKORC1 genotype on
attainment of therapeutic INR and dose, effect of VKORC1
genotype on liver protein expression, relationship between S-
warfarin clearance and CYP2C9 genotype, effect of kidney function
on S-warfarin clearance, relationship between VKORC1 genotype
and Imax. Mann-Whitney U’s test was employed to examine
gender effect on S-warfarin clearance and warfarin indication
effect on Imax. A two-tailed P-value of less than 0.05 was
considered significant for all analyses. Statistical analysis was
performed with the use of GraphPad Prism v.5.0 (GraphPad, La
Jolla, CA) or SPSS v. 17.0 (SPSS, Chicago, IL).
Results
PK-PD model performance
We fitted the individual patient S-warfarin plasma levels during
the first 9 days of therapy to a one-compartment PK model
(Figure 1A) to furnish estimates of S-warfarin clearance. The S-
warfarin clearance estimated here was similar to that previously
observed.[39] Moreover, good fits to individual patient levels with
the PK model were obtained (Figure 1C). Overall, the PK model
was sufficiently accurate in describing the data as linear regression
analysis for predicted and actual S-warfarin concentrations yielded
a coefficient of determination (r
2) of 0.91, with a slope of 0.92
(Figure 1D). The mean absolute error (MAE) between estimated
and actual was 0.04 mg/mL, and 88% of these estimated values
were within 25% of actual concentrations.
An indirect response model was used to estimate maximal
inhibitory factor (Imax), the PD parameter related to the amount of
hepatic VKOR enzyme. Here, the S-warfarin plasma concentra-
tion-INR response relationship is governed by the parameters IC50
(related to warfarin affinity to VKOR) and Imax, where at constant
IC50, increasing Imax enhances drug sensitivity (Figure 1B).
Individual predicted S-warfarin concentrations estimated from
Determinants of Warfarin PK-PD
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inputs for the PD model. Fits to individual patient INRs over the
initiation period were good (Figure 1E). Linear regression analysis
for predicted and actual INR values of the entire data set yielded
an r
2 of 0.89, with a slope of 0.91 (Figure 1F). The MAE was 0.17,
and 90% of these estimated values were within 25% of actual INR.
Determinants of S-warfarin clearance
Mean S-warfarin clearance was 7.5 L/day (SD 3.4) with a range
of 0.8 to 20.8, indicating a more than 20-fold interindividual
variability in S-warfarin PK (Figure 2A). S-warfarin clearance was
significantly associated with CYP2C9 genotype with mean
clearance values of 8.1, 7.0, 4.3, 4.5, and 2 L/day, for CYP2C9
*1/
*1,
*1/
*2,
*1/
*3,
*2/
*2, and
*2/
*3 genotypes, respectively
(Figure 2B). Interestingly, lower S-warfarin clearance was observed
in patients with decreased renal function as estimated by
glomerular filtration rate (eGFR) (Figure 2C, P,0.0001). The
cohort average eGFR was 91 mL/min/1.73 m
2 (SD 23) with a
range of 22 to 140. Moreover, eGFR was significantly decreased
with increase in age (P,0.0001, data not shown). Gender also had
an influence on S-warfarin clearance, where on average, females
had significantly lower clearance compared to males (Figure 2D,
P,0.001). With stepwise regression, clearance was found to be
dependent on CYP2C9
*3 allele, kidney function, gender, and
CYP2C9
*2 allele, in order of covariate entry into the regression
equation. VKORC1 genotype was without influence on S-warfarin
clearance. The r
2 of the final model for clearance estimation was
36.5%. Parameter estimates of the final clearance model and
bootstrap validation results are given in Table 1.
Therapeutic S-warfarin plasma concentration correlates
with VKORC1 genotype
S-warfarin plasma concentrations on day 7/8/9 were statisti-
cally different between VKORC1 -1639G.A genotype groups
(P,0.0001) despite similar INR (Figure 3A). Patients carrying at
least one -1639G.A allele required lower plasma concentrations
than wild-type patients for similar therapeutic efficacy, and this
was gene-dose dependent (Figure 3A, 3B). The mean plasma S-
warfarin concentrations for VKORC1 A/A, G/A, and G/G
genotype groups were 0.291 ng/mL (SD 0.157), 0.347 ng/mL
(0.170), and 0.503 ng/mL (0.217), corresponding to mean
warfarin daily doses of 4.4 mg (2.7), 5.0 mg (2.5) and 7.6 mg
(3.0), respectively.
Determinants of S-warfarin PD
The mean Imax value for subjects was 2.7 (SD 1.0), with a range
of 0.3 to 6.9, demonstrating a more than 20-fold interindividual
variability in S-warfarin PD (Figure 3C). A significant relationship
between VKORC1 -1639G.A genotype and Imax (Figure 3D,
P,0.0001) was observed. The mean Imax values for VKORC1 A/A,
G/A, and G/G genotypes were 3.7 (SD 1.2), 2.8 (1.0) and 2.2
(0.7), respectively.
Stepwise regression analysis indicated that Imax was dependent
on VKORC1 genotype, indication for warfarin, pre-treatment
plasma proteins induced by vitamin K absence (PIVKA-II)
concentration, CYP4F2 1297C.T genotype, and weight, in order
of covariate entry into the regression equation. The r
2 of the final
model for Imax estimation was 41%. Parameter estimates of the
final Imax model and the bootstrap validation results are given in
Table 2. The mean baseline PIVKA-II concentration was 7.1 ng/
mL (SD 4.8), with a range of 1.8 to 30.6, indicating that majority
of our patients did not exhibit vitamin K deficiency. Imax was
greater in patients with AF than VTE, denoting that VTE patients
were more resistant to warfarin’s therapeutic effect. Moreover,
there was an additive effect of VKORC1 genotype and indication,
where VTE patients had lower Imax than AF patients irrespective
of VKORC1 genotype (Figure 3E). VTE patients who were
VKORC1 G/G carriers had the lowest average Imax (2.1) while
AF and A/A carriers had the highest Imax (4.4). These findings
imply that differences in INR response would be evident between
patients with AF and VTE when warfarin is initiated by a
common dosing protocol. Indeed, we found a more rapid response
in patients with AF in comparison to VTE over the first week of
therapy (Figure 3F), despite that the WRAPID protocol eliminated
the previously known genetic and clinical contributors to early
response variability.[29]
Correlation of VKORC1 genotype to hepatic VKOR protein
levels
With Western blot analysis, hepatic microsomal VKOR had
electrophoretic mobility consistent with an 18 kDa protein while
the two immunoreactive bands observed in over-expressed VKOR
control samples likely represent differentially glycosylated forms of
the protein (Figure 4A, 4B, 4C). VKOR protein level was
significantly correlated to VKORC1 genotype (Figure 4D, P,0.05),
where the VKORC1 G allele was associated with higher liver
enzyme level than the A allele.
Simulated anticoagulation response with different
warfarin initiation protocols
To demonstrate the utility of the PK-PD model, we simulated
and compared INR response profiles of individuals with different
combinations of covariates using different published dose initiation
schemes.[25,29,40,41,42] Specifically, we compared response-time
curves of typical patients following initiation with our WRAPID
protocol,[29] the Kovacs nomogram (non-pharmacogenetics,
validated in VTE) with the day 8 dose refinement algorithm,[42]
and finally, initiation with the pharmacogenetics-based as well as
clinical-only maintenance dose algorithms available at www.
warfarindosing.org incorporating the recently published day 4
dose refinement algorithm[25,40]. Doses were adjusted according
to simulated INR values on days 3, 5, and 8 for WRAPID and
Kovacs and on day 4 for warfarindosing.org as per nomogram.
Clearance and Imax values were calculated based on regression
equations (Tables 1 and 2) for various VKORC1 and CYP2C9
genotype combinations in typical AF and VTE patients.
Homozygous CYP2C9
*3 patients were not considered in the
simulations as we did not encounter such individuals in our
population. We used CYP4F2 wild-type C/C genotype (increased
sensitivity) for all calculations of Imax. Figure 5 illustrates the
predicted effect of VKORC1 or CYP2C9 variant allele burden on
responses of AF and VTE patients initiated with WRAPID
Figure 1. PK-PD model performance. (A) Model simulated S-warfarin plasma concentration-time profiles after single dose with CYP2C9 variant
alleles. (B) Model simulated steady-state therapeutic INR (2.5) vs. S-warfarin plasma concentration with varying Imax corresponding to VKORC1 -
1639G.A genotype. (C) Model fit of measured S-warfarin concentrations in a single patient. (D) Scatter plot of actual vs. predicted S-warfarin plasma
concentration throughout the initiation phase (coefficient of determination, r
2=0.91, n=459). The diagonal line represents the unity line. (E) Model
fit of measured anticoagulation INR response values in the same patient as in (C). (F) Scatter plot of actual vs. predicted INR during the initiation phase
(r
2=0.89, n=459). The diagonal line represents the unity line. Imax, maximal inhibitory factor; INR, international normalized ratio.
doi:10.1371/journal.pone.0027808.g001
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Entry into model Predictor Variable B Standard error 95% CI R
2 after entry (%) P in final model
- Intercept 3.105 0.072 2.966, 3.248 - ,0.0001
1 CYP2C9
*3, per allele 20.812 0.151 21.093, 20.510 14.3 ,0.0001
2e G F R
a 20.278 0.080 20.417, 20.145 24.9 ,0.0001
3 Gender (F) 20.357 0.081 20.511, 20.186 32.3 ,0.0001
4 CYP2C9
*2, per allele 20.274 0.080 20.427, 20.113 36.5 ,0.0001
CI, confidence interval; CYP2C9, cytochrome P450 2C9; eGFR, estimated glomerular filtration rate in mL/min/1.73m
2; F, female.
aCoded as follows: $90 mL/min/1.73 m
2, 0; 60–89, 1; 30–59, 2; 15–29, 3; #15, 4.
doi:10.1371/journal.pone.0027808.t001
Figure 2. Determinants of S-warfarin clearance. (A) Frequency distribution of estimated S-warfarin clearance, shown as percent of total patients
for each bin. (B) Relationship between CYP2C9 genotype and S-warfarin clearance. Lines represent mean clearance. (C) S-warfarin clearance is
significantly correlated with kidney function, as defined by eGFR. (D) Observed S-warfarin clearance segregated by gender. Lines represent mean
clearance. eGFR, estimated glomerular filtration rate.
* P,0.05,
** P,0.005,
***P,0.0005.
doi:10.1371/journal.pone.0027808.g002
Determinants of Warfarin PK-PD
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27808Determinants of Warfarin PK-PD
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27808nomogram (5A, 5B), Kovacs nomogram (5C, 5D), warfarindo-
sing.org genetics (5E, 4F), and clinical nomogram (5G, 5H),
respectively. The simulated response curves indicate that increased
possession of variant alleles is associated with slightly greater time
above therapeutic INR with fixed 10 mg loading doses and
iterative response-based Kovacs nomogram than initiation strat-
egies which incorporate genetic and patient factors. In contrast,
pharmacogenetics-guided initiation schemes eliminated the geno-
type-dependent response differences. Furthermore, pharmacoge-
netics-guided dosing nomograms resulted in comparable rise to
optimal anticoagulation response among different genotypes
within groups of AF and VTE patients. Evidently, loading dose
was not used in simulations of patients initiated with warfarindo-
sing.org and thus, the time to reach optimal anticoagulation was
approximately 3 days slower as compared to the WRAPID
nomogram. Simulations with the warfarindosing.org clinical
algorithm indicate that there would be significant differences in
initial INR responses as the burden of genetic variants increases.
Discussion
Warfarin initiation is a challenging therapeutic phase, associat-
ed with the highest occurrence of major bleeding events and
thromboembolism.[43,44,45,46] Thus, effective initiation proto-
cols that pre-emptively account and adjust for interindividual
variability have significant potential to improve warfarin antico-
agulation therapy.
A major contributor to dose requirement and response is S-
warfarin clearance. The analysis demonstrates that kidney function,
gender, CYP2C9
*2 and
*3 genotype are major determinants of S-
warfarin clearance.Thefindingthat S-warfarinclearanceisreduced
in renal impairment supports recent studies that found relationships
between both warfarin dose requirement and propensity for over-
anticoagulationwith kidney function.[47,48]Althoughagehasbeen
correlated with decreased warfarin clearance, we failed to observe
this relationship after multivariate regression that included both age
and eGFR.[7,8,9,27] It is plausible that age, as a contributor to
clearance, somewhat reflects age-related decline in renal function.
Indeed,wenotethatincludingeGFRasanadditionalfactorintothe
regression analysis resulted in 36.5% of clearance variation
explained, while only 27.6% of this variation was accounted for
when eGFR was absent and age included in the analysis.
Interestingly, gender was a significant independent contributor to
S-warfarinclearanceinthis study,withfemales having22% lowerS-
warfarin clearance than males. While females require lower doses
than males for similar anticoagulation quality and efficacy [49],
there remain conflicting reports on the role of gender on S-warfarin
pharmacokinetics. [7,8,27] Drug interactions, particularly with
amiodarone and antifungals, are significant contributors to variable
warfarin response.[50,51,52] Because of the limited number of
patients in this cohort taking these medications, we did not find
associations between concomitant drugs and warfarin clearance.
Larger studies in patients are required to better characterize the
quantitative influence of co-administered drugs on warfarin
clearance.
While determinants of S-warfarin PK have been studied, less is
known regarding determinants of the S-warfarin plasma concen-
tration-response relationship. We identified VKORC1, weight,
indication for warfarin, PIVKA-II and CYP4F2 genotype as
significant predictors of S-warfarin Imax, the PD parameter that
governs the magnitude of observed anticoagulation INR response.
In addition, we demonstrate that promoter -1639G.A SNP
results in lower hepatic VKOR protein expression. In concor-
dance with that previously observed for warfarin-stabilized
patients,[53] there was a significant relationship between VKORC1
genotype and S-warfarin plasma concentrations at the end of the
initiation phase where therapeutic INR was achieved. Taken
together, the VKORC1 -1639G.A promoter SNP confers lower
hepatic expression, thus lower plasma S-warfarin concentrations
and dose required for optimal anticoagulation.
The finding that Imax differences exist between AF and VTE
patients, following adjustment of confounding variables such as
age and weight, suggests that indication for treatment maybe a
prominent contributor to response variability during initiation.
This may be attributed to different coaguability states among
patients during therapy initiation, in addition to inherent disease
differences between the two subsets of patients. Further studies are
required to investigate the physiological basis mediating the PD
Figure 3. Determinants of maximal inhibitory factor, Imax. (A) Box-and-whisker plots of S-warfarin plasma concentration and INR on days 7/8/9
segregated by VKORC1 -1639G.A genotype. Box-and-whisker plots representing VKORC1 gene-dose effect during initiation. The top and bottom of
the boxes represents 25
th and 75
th percentile, respectively; median is represented by the middle line, whiskers are the 95% CI, and outliers are
identified as closed circles. (B) Warfarin daily dose on days 7/8/9 with respect to VKORC1 genotype. (C) Frequency distribution of estimated Imax,
shown as percent of total patients for each bin. (D) Association between VKORC1 genotype and Imax. Results are represented as mean with standard
deviation. (E) Additive effect of indication for warfarin therapy and VKORC1 genotype on Imax. (F) INR time course for patients with AF and VTE over
the initial 10 days of therapy with common genetics-guided dosing protocol. Results are represented as mean with 95% CI of the standard error.
AF, atrial fibrillation; INR, international normalized ratio; VTE, venous thromboembolism.
* P,0.05,
** P,0.01,
*** P,0.001,
**** P,0.0001.
doi:10.1371/journal.pone.0027808.g003
Table 2. Multiple linear regression analysis of independent predictors of Imax.
Entry into model Predictor Variable B Standard error 95% CI R
2 after entry (%) P in final model
- Intercept 1.383 0.101 1.156, 1.570 - ,0.0001
1 VKORC1, per allele 0.211 0.030 0.148, 0.267 26.3 ,0.0001
2 Indication (VTE) 20.281 0.049 20.380, 20.190 34.9 ,0.0001
3 PIVKA-II (ng/mL) 0.017 0.007 0.005, 0.033 37.9 ,0.05
4 CYP4F2, per allele 20.072 0.031 20.133, 20.009 39.6 ,0.05
5 Weight (Kg) 0.002 0.001 0.000, 0.004 41.0 ,0.05
CI, confidence interval; CYP4F2, cytochrome P450 4F2; Imax, maximal inhibitory factor; PIVKA-II, proteins induced by vitamin K absence; VKORC1, vitamin K epoxide
reductase complex subunit 1; VTE, venous thromboembolism.
doi:10.1371/journal.pone.0027808.t002
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know whether this dynamic difference would diminish or be
maintained throughout the course of anticoagulation therapy.
Indeed, indication for anticoagulation was an independent
determinant of maintenance dose in the present cohort and one
dose algorithm (warfarindosing.org) incorporates VTE as a factor
requiring higher warfarin maintenance dose.[25] In the present
study population, we find a 2.3 mg/day difference in mean
maintenance dose between AF and VTE patients. This value is
greater than the 0.7 mg/day difference predicted by the WRAPID
maintenance dose algorithm when accounting for the average age
(21 yrs) and weight (6.5 kg) differences between the AF and VTE
groups. While a component of this maintenance dose difference is
likely related to the lack of consideration of renal function
differences among the disease groups with the WRAPID
algorithm, the current PK-PD analysis suggests that indication
for anticoagulation remains a contributor to warfarin dose.
In agreement with previous studies linking CYP4F2 genotype
and vitamin K intake to warfarin dose requirement,[18,23,24] our
data demonstrate that pre-treatment plasma PIVKA-II levels and
CYP4F2 1297G.A genotype affects S-warfarin PD sensitivity
during initiation. PIVKA-II, a des-carboxylated form of pro-
thrombin, is a direct biomarker for liver vitamin K status and
dietary intake.[54] We did not find a relationship between
PIVKA-II level and CYP4F2 genotype during statistical analysis
or collinearity during stepwise regression of Imax for this cohort of
patients. Taken together, our findings highlight the importance of
the balance between the VKOR agonist (vitamin K) and
antagonistic (warfarin) concentrations in achievement and main-
tenance of optimal anticoagulation, particularly during initiation.
An important outcome of this study was the formulation of an
overall PK-PD model that incorporates the determinants of
warfarin kinetics and response. We demonstrate the utility of the
model to predict S-warfarin concentrations and INR response
curves in simulated individuals initiated with different protocols.
The simulations predict substantial differences in initial anticoag-
ulation responses depending on the initiation scheme, indication
for warfarin treatment and burden of genetic variation in CYP2C9
and VKORC1. Within all of the initiation protocols examined, AF
patients would be predicted to have greater initial response than
VTE. The indication difference exaggerates the effect of genetic
polymorphisms on response especially for initiation protocols that
do not consider CYP2C9 and VKORC1 genotypes. Interestingly,
the simulations indicate that the Kovacs nomogram results in a
safe and rapid initiation in VTE patients, consistent with the
observed good safety profile in real-world patients.[41,55] On the
other hand, the Kovacs nomogram is predicted to be less optimal
for in AF as it may pose an over-anticoagulation risk in these
patients. Simulations in patients initiated with pharmacogenetics-
based dosing algorithms suggest they would be safe and effective
for both patient populations and that the response curves of
individuals possessing variant alleles were similar. In comparing
initiation with WRAPID and warfarindosing.org, time to thera-
peutic range was delayed without the use of loading dose. In the
case for VTE, delayed attainment of therapeutic INR may have
economic consequences as bridging therapy with low molecular
weight heparins would need to be extended when loading doses
are not administered. The simulations also forecast the time-
course of initial INR responses in the large multi-centered
randomized clinical trial comparing outcomes between pharma-
Figure 4. The influence of VKORC1 -1639G.A promoter genotype on hepatic VKOR protein expression levels. (A, B, C) VKOR expression
determined in 17 healthy human livers by Western blot analysis. The band intensity was normalized to HLM100. A positive control sample was
included on each blot. (D) Semiquantitative measurement of hepatic expression in relation to VKORC1 genotype.
* P,0.01.
doi:10.1371/journal.pone.0027808.g004
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PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27808cogenetic and clinical-based warfarin dosing (Clarification of
Optimal Anticoagulation Through Genetics, COAG trial) as
defined by warfarindosing.org algorithms. The model predicts
significant differences in INR response between the two dosing
methods during initiation, particularly for patients harbouring
variant alleles.
While maintenance dose prediction algorithms typically utilize a
number of clinical and genetic parameters, these models are not
designed to delineate how each parameter affects warfarin PK, PD
or both. The formal PK-PD analysis described herein demon-
strates that the interindividual variation in both components of the
overall warfarin response can be separated and quantitatively
ascribed to respective combinations of non-genetic and genetic
factors. Moreover, our integrated PK-PD model allows for robust
prediction of INR response profiles particularly during initiation
phase of therapy following any initiation-dose scheme, in addition
to assessment of covariate effect on responses by altering PK or PD
estimates. It should be noted that based on the current model form
and input parameters, the PK determinants only account for
36.5% of the variability observed in S-warfarin clearance, while
PD determinants accounted for 41% of the Imax variation. For this
reason, it is expected that the current model would not provide
precise response estimations on an individual patient basis due to
the large variation still unaccounted for.
In conclusion, the data presented here provides additional
insight into the combination of patient characteristics contributing
to warfarin PK and PD variability, in turn allowing better
prediction of anticoagulation response outcomes without the need
for intensive sampling of drug concentrations. Until there is a
better understanding of additional determinants of PK and PD
variation, and better quantitative characterization of drug-drug
interactions, the current model may be useful for predicting
outcomes in populations of patients within the context of
comparing the effectiveness of various dosing algorithms in early
attainment and maintenance of therapeutic INR responses and in
guiding future study designs.
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